Cargando…

Medullary thyroid carcinoma (MTC): unusual metastatic sites

SUMMARY: Medullary thyroid carcinoma (MTC) has a varying clinical course; distant metastases are frequently present even at diagnosis. We present two MTC cases with unusual metastatic sites. Two female patients are presented with slow progressive MTC. The first case developed distant metastases 23 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazakou, Paraskevi, Simeakis, George, Alevizaki, Maria, Saltiki, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495720/
https://www.ncbi.nlm.nih.gov/pubmed/34551391
http://dx.doi.org/10.1530/EDM-21-0063
_version_ 1784579606935764992
author Kazakou, Paraskevi
Simeakis, George
Alevizaki, Maria
Saltiki, Katerina
author_facet Kazakou, Paraskevi
Simeakis, George
Alevizaki, Maria
Saltiki, Katerina
author_sort Kazakou, Paraskevi
collection PubMed
description SUMMARY: Medullary thyroid carcinoma (MTC) has a varying clinical course; distant metastases are frequently present even at diagnosis. We present two MTC cases with unusual metastatic sites. Two female patients are presented with slow progressive MTC. The first case developed distant metastases 23 years after diagnosis and underwent locoregional therapies. At the same time a breast mass developed representing MTC metastasis. Treatment with vandetanib led to long-term disease stabilization. The second patient is presented with metastases in the pancreas 13 years after diagnosis. Shortly, a painful mass developed in the mandible and metastasis of MTC was diagnosed. Disease progression was recorded 20 months after the initiation of local and systemic therapy. Such cases have only rarely been reported in the literature and highlight the need for prompt recognition of unexpected MTC metastases. LEARNING POINTS: Unusual sites of metastasis may appear in patients with medullary thyroid carcinoma (MTC) years after the initial diagnosis. Although rare, unexpected MTC metastases highlight the need for prompt recognition and appropriate treatment. Local recurrences accompanied by inappropriately low calcitonin levels should prompt further investigation for possible distant metastatic disease. Systemic treatment with tyrosine kinase inhibitors may be effective even in patients with unusual metastases from MTC.
format Online
Article
Text
id pubmed-8495720
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-84957202021-10-12 Medullary thyroid carcinoma (MTC): unusual metastatic sites Kazakou, Paraskevi Simeakis, George Alevizaki, Maria Saltiki, Katerina Endocrinol Diabetes Metab Case Rep Unique/Unexpected Symptoms or Presentations of a Disease SUMMARY: Medullary thyroid carcinoma (MTC) has a varying clinical course; distant metastases are frequently present even at diagnosis. We present two MTC cases with unusual metastatic sites. Two female patients are presented with slow progressive MTC. The first case developed distant metastases 23 years after diagnosis and underwent locoregional therapies. At the same time a breast mass developed representing MTC metastasis. Treatment with vandetanib led to long-term disease stabilization. The second patient is presented with metastases in the pancreas 13 years after diagnosis. Shortly, a painful mass developed in the mandible and metastasis of MTC was diagnosed. Disease progression was recorded 20 months after the initiation of local and systemic therapy. Such cases have only rarely been reported in the literature and highlight the need for prompt recognition of unexpected MTC metastases. LEARNING POINTS: Unusual sites of metastasis may appear in patients with medullary thyroid carcinoma (MTC) years after the initial diagnosis. Although rare, unexpected MTC metastases highlight the need for prompt recognition and appropriate treatment. Local recurrences accompanied by inappropriately low calcitonin levels should prompt further investigation for possible distant metastatic disease. Systemic treatment with tyrosine kinase inhibitors may be effective even in patients with unusual metastases from MTC. Bioscientifica Ltd 2021-09-01 /pmc/articles/PMC8495720/ /pubmed/34551391 http://dx.doi.org/10.1530/EDM-21-0063 Text en © The authors https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unique/Unexpected Symptoms or Presentations of a Disease
Kazakou, Paraskevi
Simeakis, George
Alevizaki, Maria
Saltiki, Katerina
Medullary thyroid carcinoma (MTC): unusual metastatic sites
title Medullary thyroid carcinoma (MTC): unusual metastatic sites
title_full Medullary thyroid carcinoma (MTC): unusual metastatic sites
title_fullStr Medullary thyroid carcinoma (MTC): unusual metastatic sites
title_full_unstemmed Medullary thyroid carcinoma (MTC): unusual metastatic sites
title_short Medullary thyroid carcinoma (MTC): unusual metastatic sites
title_sort medullary thyroid carcinoma (mtc): unusual metastatic sites
topic Unique/Unexpected Symptoms or Presentations of a Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495720/
https://www.ncbi.nlm.nih.gov/pubmed/34551391
http://dx.doi.org/10.1530/EDM-21-0063
work_keys_str_mv AT kazakouparaskevi medullarythyroidcarcinomamtcunusualmetastaticsites
AT simeakisgeorge medullarythyroidcarcinomamtcunusualmetastaticsites
AT alevizakimaria medullarythyroidcarcinomamtcunusualmetastaticsites
AT saltikikaterina medullarythyroidcarcinomamtcunusualmetastaticsites